This company develops nanosensors for rapid, low-cost, and highly sensitive in vitro diagnostics across infectious diseases, autoimmune disorders, and oncology. Their technology enables real-time readout and point-of-care testing, moving diagnostics away from centralized labs. The goal is to facilitate early disease detection and support the transition to personalized medicine.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional diagnostic methods often suffer from delays, high costs, and limited accessibility, hindering timely treatment and preventative care, particularly for marginalized communities. Current diagnostic approaches also typically require the presence of symptoms before testing can occur.
Solution
NIVD is developing nanosensors for in-vitro diagnostics to enable rapid and accurate detection of diseases, including infectious diseases, autoimmune disorders, and cancers, at the pre-symptomatic stage. The company's technology aims to overcome the limitations of conventional diagnostics by providing low-cost, lab-free testing with real-time results. NIVD's nanosensors are designed to detect diseases almost instantly, facilitating precision medicine through early intervention and personalized treatment plans. The solution offers point-of-care and self-testing capabilities, with long shelf life and no specific storage requirements.
Target Audience
The primary target audience includes healthcare providers, researchers, and individuals seeking accessible and early disease detection solutions.
Features
- Nanosensors for rapid detection of diseases in seconds
- Low-cost diagnostic testing
- Lab-free operation, enabling point-of-care testing
- High accuracy and sensitivity
- Real-time readout of results
- Suitable for self-testing
- Long shelf life with no special storage requirements